Leading life-sciences companies in LATAM have partnered with prestigious public institutions to discover, develop and manufacture innovative biopharmaceuticals. With state-of-the-art technology and a production platform, the objective of this consortium is to contribute to next-generation solutions for human and animal health.
The partnership model enables articulating the prestigious tradition in scientific research of the public sector with the technology and production and managing capabilities of the private sector. Our networking model includes, among others, the biotech companies Chemo, mAbxience, Elea, Sinergium Biotech and Biogénesis Bagó, as well as the prestigious University of Buenos Aires, National Quilmes University, the Garrahan Children´s Hospital and the National Scientific and Technical Research Council (CONICET).
We lead with original lines of research in cancer, rare pediatric diseases, and other high-prevalence disorders. We have several molecules in early as well as late development stages. Our portfolio of biotechnology products includes the first therapeutic vaccine for the treatment of lung cancer (Vaxira®), a novel desmopressin analog for human and animal health and numerous biosimilars.